OC
TRVI icon

Oppenheimer & Co’s Trevi Therapeutics TRVI Stock Holding History

Oppenheimer & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
100,027
-671
-0.7% -$7.51K 0.01% 792
2025
Q4 		$1.26M Buy
100,698
+2,030
+2% +$23.5K 0.02% 709
2025
Q3 		$903K Sell
98,668
-1,157
-1% -$8.68K 0.01% 945
2025
Q2 		$546K Sell
99,825
-612
-0.6% -$3.81K 0.01% 1108
2025
Q1 		$632K Buy
100,437
+19,034
+23% +$90.8K 0.01% 997
2024
Q4 		$335K Sell
81,403
-544
-0.7% -$1.74K 0.01% 1212
2024
Q3 		$274K Buy
81,947
+21,128
+35% +$62.8K ﹤0.01% 1285
2024
Q2 		$181K Buy
60,819
+404
+0.7% +$1.12K ﹤0.01% 1349
2024
Q1 		$208K Buy
+60,415
New +$135K ﹤0.01% 1328

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return